Trial Profile
Prognostic factor for dose limiting toxicity to chemotherapy in patients with metastatic renal cell carcinoma (mRCC).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 04 Dec 2015 New trial record